| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2019: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2018: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Outline of Final Research Achievements |
It is difficult to treat primary brain tumors. Especially, although chemoradiation is performed, the prognosis of glioblastomas is exremely poor. Cancer stem cell is important and may exist in hyperglycometabolic area. It is known that cancer stem cell has resistance for chemoradiation. Positron emission tomography (PET) can visualize glucose and amino acid metabolization. We developed the FDG/Methionine Index PET Imaging. This method is expected to visualize more detailed hyperglycometabolic area. We evaluate this method for diagnosis of brain tumors and the prognosis.
We revealed the correlation between this method and pathological grade. For the prognosis, although there is the trend in between standerdized uptake value (SUV) and the prognosis, there is no significant difference among them. We will evaluate them in increasing the numbar of cases and follow up period in the future.
|
